

Press release from Emotra AB (publ)
Göteborg, March 27, 2015

EDOR at international conventions

Emotra's method for assessing suicide risk, EDOR, is being presented at more and more scientific conventions across Europe. We will be carrying out a number of activities, seminars, workshops and poster presentations at the European Psychiatric Association's global convention, which will take place on March 28–31, 2015, in Vienna. In the past week, Professor Marco Sarchiapone has presented EDOR at large national psychiatric conventions in Romania and Israel. Lars-Håkan Thorell and Marco Sarchiapone will be making further appearances at a number of conventions later this year.

Emotra's CEO, Claes Holmberg, our Chief of Research and the inventor of the EDOR method, Lars-Håkan Thorell, as well as Professor Marco Sarchiapone will be participating in a number of events at the Vienna convention. The convention will also feature a seminar dedicated to EDOR. The method will be presented in a workshop where future business opportunities in the psychiatric field will also be discussed. Furthermore, we will be displaying posters about EDOR and the goals of our ongoing multi-centre study. We are not able to present any results yet, since all tested patients need to be monitored for a full year after initial testing.

We will, however, underscore the fact that the number of reported tests has increased dramatically. After our problems transferring EDOR test data last autumn, our data reporting is now in pace with Emotra's and all of the collaborating clinics' expectations. So far, 170 patients have been tested; 140 of these in the last 5 weeks. The inflow of new tests is now working as planned. Several of the clinics participating in our multi-centre study will also be present at the Vienna convention. All of these clinics will be participating in an evening work meeting hosted by Emotra.

These clinics are very dedicated to our cause, and our relationship with these clinics is very good. They all maintain that the method is easy to use and, once last autumn's data transfer problems were resolved, easy to get started with, and neither the testers nor the participants themselves perceive these tests as cumbersome or time-consuming.

For further information, please contact: *Claes Holmberg, CEO, telephone: +46 708 25 45 47, E-mail: claes@emotra.se*

Emotra AB is listed on AktieTorget and the company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.